cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Solid Biosciences Inc
13 own
29 watching
Current Price
$2.69
$0.2
(8.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
92.75M
52-Week High
52-Week High
8.61750
52-Week Low
52-Week Low
2.42000
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization92.75M
icon52-Week High8.61750
icon52-Week Low2.42000
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Solid Biosciences Inc do?
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company s lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Solid Biosciences Inc make?
News & Events about Solid Biosciences Inc.
Globe Newswire
5 months ago
CHARLESTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Solid management will participate in a fireside chat at Chardans 7th Annual Genetic ...
Globe Newswire
6 months ago
- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - - Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patients with ...
Globe Newswire
6 months ago
CHARLESTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the BMO Biopharma ...
Globe Newswire
7 months ago
CHARLESTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the SVB Securities Global ...
Globe Newswire
8 months ago
- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy intended for treatment of patients with Duchenne muscular dystrophy - - White paper submitted to the U.S...
Frequently Asked Questions
Frequently Asked Questions
What is Solid Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Solid Biosciences Inc shares?
plus_minus_icon
How can I buy Solid Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Solid Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Solid Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Solid Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Solid Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Solid Biosciences Inc?
plus_minus_icon
What percentage is Solid Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Solid Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.69
$0.2
(8.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
GAMIDA CELL LTD
GAMIDA CELL LTD
$1.02
$0.03 (2.50 %)
AVROBIO INC
AVROBIO INC
$1.54
$-0.01 (-0.58 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$2.34
$-0.07 (-2.90 %)
Gritstone Oncology Inc
Gritstone Oncology Inc
$1.73
$0.17 (10.90 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
GAMIDA CELL LTD
GAMIDA CELL LTD
$1.02
$0.03 (2.50 %)
AVROBIO INC
AVROBIO INC
$1.54
$-0.01 (-0.58 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$2.34
$-0.07 (-2.90 %)
Gritstone Oncology Inc
Gritstone Oncology Inc
$1.73
$0.17 (10.90 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00